









Mercado
/
Acciones
/
nasdaq-lqda
/

Liquidia Corp

LQDA

28.040USD

+1.100+4.08%

Cierre 11/14, 16:00（ET）Cotizaciones retrasadas 15 min

2.43BCap. mercado

PérdidaP/E TTM



Liquidia Corp

28.040

+1.100+4.08%

Descripción general Compañía Finanzas Análisis

Descripción general

Compañía

Finanzas

Análisis

Más Datos de Liquidia Corp Compañía

Liquidia Corporation is a biopharmaceutical company. The Company is focused on the development, manufacture and commercialization of products that address unmet patient needs, with a focus directed towards rare cardiopulmonary diseases, such as pulmonaryarterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The Company operates through its wholly owned operating subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Its proprietary PRINT technology is a particle engineering platform, which enable precise production of uniform drug particles. Its lead product candidate is YUTREPIA for the treatment of PAH and PH-ILD. YUTREPIA is an inhaled dry powder formulation of treprostinil designed with PRINT to improve the therapeutic profile of treprostinil by enhancing deep lung delivery while using a convenient, dry-powder inhaler (DPI) and by achieving higher dose levels than the labeled doses of current inhaled therapies.

Información de Liquidia Corp



Símbolo de cotizaciónLQDA

Nombre de la empresaLiquidia Corp

Fecha de salida a bolsaJul 26, 2018

Director ejecutivoDr. Roger A. Jeffs, Ph.D.

Número de empleados157

Tipo de seguridadOrdinary Share

Fin del año fiscalJul 26

Dirección419 Davis Drive

CiudadMORRISVILLE

Bolsa de valoresNASDAQ Capital Market Consolidated

PaísUnited States of America

Código postal27560

Teléfono19193284400

Sitio Webhttps://www.liquidia.com/

Símbolo de cotizaciónLQDA

Fecha de salida a bolsaJul 26, 2018

Director ejecutivoDr. Roger A. Jeffs, Ph.D.

Ejecutivos de Liquidia Corp



Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Dr. Roger A. Jeffs, Ph.D.

Chief Executive Officer, Director

2.11M

-0.30%

Mr. Russell Schundler, J.D.

General Counsel, Secretary

365.84K

-1.10%

Mr. Rajeev Saggar, M.D.

Chief Medical Officer

169.42K

-29.64%

Mr. Scott Moomaw

Chief Commercial Officer

143.78K

-1.23%

Mr. Jason Adair

Chief Business Officer

142.35K

+1.44%

Mr. Michael Kaseta

Chief Financial Officer, Chief Operating Officer

85.98K

-6.32%

Mr. Damian Degoa

Independent Director

66.11K

+38.55%

Mr. Arthur S. Kirsch

Independent Director

50.40K

+57.49%

Ms. Katherine (Katie) Rielly-Gauvin

Independent Director

18.40K

Dr. Joanna C. Horobin

Independent Director

13.40K

-27.18%

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Dr. Roger A. Jeffs, Ph.D.

Chief Executive Officer, Director

2.11M

-0.30%

Mr. Russell Schundler, J.D.

General Counsel, Secretary

365.84K

-1.10%

Mr. Rajeev Saggar, M.D.

Chief Medical Officer

169.42K

-29.64%

Mr. Scott Moomaw

Chief Commercial Officer

143.78K

-1.23%

Mr. Jason Adair

Chief Business Officer

142.35K

+1.44%

Mr. Michael Kaseta

Chief Financial Officer, Chief Operating Officer

85.98K

-6.32%

Desglose de ingresos

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

Sin datos

Por regiónUSD

Nombre

Ganancia

Proporción

United States

14.00M

0.00%

Por negocio

Por región

Sin datos

Estadísticas de accionistas

Actualizado: hace 23 horas

Accionistas

Tipos de accionistas

Accionistas

Proporción

Caligan Partners, LP

9.33%

Farallon Capital Management, L.L.C.

7.85%

Manning (Paul B.)

7.09%

BlackRock Institutional Trust Company, N.A.

5.25%

The Vanguard Group, Inc.

4.54%

Otro

65.94%

Accionistas

Proporción

Caligan Partners, LP

9.33%

Farallon Capital Management, L.L.C.

7.85%

Manning (Paul B.)

7.09%

BlackRock Institutional Trust Company, N.A.

5.25%

The Vanguard Group, Inc.

4.54%

Otro

65.94%

Tipos de accionistas

Accionistas

Proporción

Hedge Fund

36.10%

Investment Advisor

16.71%

Investment Advisor/Hedge Fund

12.07%

Individual Investor

11.15%

Research Firm

4.04%

Corporation

2.64%

Family Office

1.88%

Private Equity

0.56%

Bank and Trust

0.44%

Otro

14.42%

Participación institucional



Actualizado: dom., 5 de oct

Periodo del informe

Número de instituciones

Acciones mantenidas

Proporción

Cambio

2025Q3

358

61.00M

70.12%

+1.28M

2025Q2

350

67.92M

79.46%

-5.32M

2025Q1

356

67.75M

79.47%

-4.91M

2024Q4

344

63.62M

75.17%

-10.09M

2024Q3

335

73.31M

89.39%

+16.42M

2024Q2

318

66.67M

87.88%

+4.98M

2024Q1

302

59.34M

79.61%

+7.64M

2023Q4

256

48.15M

70.41%

+4.56M

2023Q3

236

40.52M

62.49%

-5.87M

2023Q2

223

41.12M

63.56%

-6.16M

Actividad de los accionistas



Nombre

Acciones mantenidas

Proporción

Cambio

Cambio %

Fecha

Caligan Partners, LP

8.12M

9.43%

+300.00

+0.00%

Jun 30, 2025

Farallon Capital Management, L.L.C.

6.83M

7.94%

+2.59M

+61.19%

Jul 07, 2025

Manning (Paul B.)

6.16M

7.21%

+18.40K

+0.30%

Jun 17, 2025

BlackRock Institutional Trust Company, N.A.

4.26M

4.95%

+65.79K

+1.57%

Jun 30, 2025

The Vanguard Group, Inc.

3.58M

4.16%

+126.92K

+3.68%

Jun 30, 2025

Findell Capital Management LLC

3.00M

3.48%

+110.00K

+3.81%

Jun 30, 2025

Opaleye Management Inc.

2.48M

2.87%

+215.00K

+9.51%

Jun 30, 2025

Goldman Sachs & Company, Inc.

2.34M

2.72%

+1.56M

+200.35%

Jun 30, 2025

Jeffs (Roger A)

2.12M

2.46%

-6.42K

-0.30%

Jul 14, 2025

Legend Aggregator LP

1.86M

2.16%

-5.32M

-74.10%

Dec 31, 2024

ETFs relacionados



Actualizado: jue., 6 de nov

Nombre

Proporción

SPDR S&P Pharmaceuticals ETF

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

1.5%

Virtus LifeSci Biotech Clinical Trials ETF

1.14%

Invesco Dorsey Wright Healthcare Momentum ETF

1.09%

iShares U.S. Pharmaceuticals ETF

0.57%

Federated Hermes MDT Small Cap Core ETF

0.38%

iShares Micro-Cap ETF

0.28%

SPDR S&P Kensho New Economies Composite ETF

0.26%

Vanguard US Momentum Factor ETF

0.12%

iShares Russell 2000 Growth ETF

0.09%

SPDR S&P Pharmaceuticals ETF

Proporción2%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

Proporción1.5%

Virtus LifeSci Biotech Clinical Trials ETF

Proporción1.14%

Invesco Dorsey Wright Healthcare Momentum ETF

Proporción1.09%

iShares U.S. Pharmaceuticals ETF

Proporción0.57%

Federated Hermes MDT Small Cap Core ETF

Proporción0.38%

iShares Micro-Cap ETF

Proporción0.28%

SPDR S&P Kensho New Economies Composite ETF

Proporción0.26%

Vanguard US Momentum Factor ETF

Proporción0.12%

iShares Russell 2000 Growth ETF

Proporción0.09%

Dividendos



Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.

Fecha

Dividendos

Fecha de registro

Fecha de pago

Fecha ex-dividendo

Sin datos

División de acciones



Fecha

Tipo

Relación

Sin datos

Fecha

Tipo

Relación

Sin datos

KeyAI

